Volume 67, Issue 1, Pages (January 2005)

Slides:



Advertisements
Similar presentations
Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway  William A. Wilmer, Cynthia L. Dixon, Courtney Hebert 
Advertisements

Volume 65, Issue 6, Pages (June 2004)
Volume 65, Issue 1, Pages (January 2004)
Volume 63, Issue 6, Pages (June 2003)
Volume 65, Issue 1, Pages (January 2004)
Volume 42, Issue 1, Pages (January 2005)
Volume 58, Issue 4, Pages (October 2000)
Cyril H. Barton, Zehnmin Ni, Nosratola D. Vaziri  Kidney International 
Volume 62, Issue 4, Pages (October 2002)
Volume 68, Issue 2, Pages (August 2005)
Volume 82, Issue 6, Pages (September 2012)
Volume 79, Issue 1, Pages (January 2011)
Requirement of heat shock protein 90 in mesangial cell mitogenesis
Ding Ai, John Y.-J. Shyy, Yi Zhu  Kidney International 
Volume 62, Issue 2, Pages (August 2002)
Volume 65, Issue 1, Pages (January 2004)
Volume 58, Issue 6, Pages (December 2000)
Volume 63, Issue 4, Pages (April 2003)
Volume 65, Issue 6, Pages (June 2004)
Genistein protects the kidney from cisplatin-induced injury
Volume 79, Issue 1, Pages (January 2011)
Volume 63, Issue 6, Pages (June 2003)
Volume 59, Issue 4, Pages (April 2001)
Volume 56, Issue 6, Pages (December 1999)
Volume 68, Issue 3, Pages (September 2005)
Volume 54, Issue 6, Pages (January 1998)
Volume 59, Issue 5, Pages (May 2001)
Ischemia-reperfusion injury in renal transplantation: 3 key signaling pathways in tubular epithelial cells  Stephanie F. Smith, Sarah A. Hosgood, Michael.
Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding  Kidney International 
Fan Zhang, Yaw L. Siow, Karmin O  Kidney International 
Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats  Gopala K. Rangan, Yiping Wang, Yuet-Ching Tay,
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Gene transfer of truncated IκBα prevents tubulointerstitial injury
Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway  William A. Wilmer, Cynthia L. Dixon, Courtney Hebert 
Volume 57, Issue 3, Pages (March 2000)
Volume 75, Issue 2, Pages (January 2009)
Volume 65, Issue 3, Pages (March 2004)
Volume 61, Issue 6, Pages (June 2002)
P. Harding, L. Balasubramanian, J. Swegan, A. Stevens, W.F. Glass 
Volume 73, Issue 11, Pages (June 2008)
Volume 64, Issue 2, Pages (August 2003)
Volume 72, Issue 12, Pages (December 2007)
20-HETE in acute kidney injury
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 62, Issue 3, Pages (September 2002)
Volume 61, Issue 3, Pages (March 2002)
Volume 61, Issue 6, Pages (June 2002)
Volume 56, Issue 5, Pages (November 1999)
Ho Jae Han, Soo Hyun Park, Hyun Ju Koh, Mary Taub  Kidney International 
Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier  Ellen T. Mccarthy, R.A.M. Sharma, Mukut Sharma,
Prasun K. Datta, Elias A. Lianos  Kidney International 
Inhibition of pressure natriuresis in mice lacking the AT2 receptor
Volume 62, Issue 4, Pages (October 2002)
Volume 58, Issue 4, Pages (October 2000)
Angiotensin III increases MCP-1 and activates NF-кB and AP-1 in cultured mesangial and mononuclear cells  Marta Ruiz-Ortega, Oscar Lorenzo, Jesus Egido 
Molecular mechanisms of renal hypertrophy: Role of p27Kip1
Volume 59, Issue 5, Pages (May 2001)
Volume 68, Issue 5, Pages (November 2005)
Increased importin α protein expression in diabetic nephropathy
Volume 75, Issue 12, Pages (June 2009)
Volume 61, Issue 6, Pages (June 2002)
Role of immunocompetent cells in nonimmune renal diseases
Volume 58, Issue 3, Pages (September 2000)
Volume 67, Issue 6, Pages (June 2005)
Jens Gaedeke, Nancy A. Noble, Wayne A. Border  Kidney International 
Effect of prenatal dexamethasone on rat renal development
Volume 72, Issue 2, Pages (July 2007)
Bismarck Amoah-Apraku, Mao-Zhong Fang, Nicolas J. Guzman, M.D 
Deon G. Uffort, Elizabeth A. Grimm, Julie A. Ellerhorst 
Volume 54, Issue 2, Pages (August 1998)
Presentation transcript:

Volume 67, Issue 1, Pages 248-258 (January 2005) Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II– induced renal damage  Jorgen Theuer, Erdenechimeg Shagdarsuren, Dominik N. Muller, E.V.A. Kaergel, Horst Honeck, Joon-Keun Park, Anette Fiebeler, Ralf Dechend, Hermann Haller, Friedrich C. Luft, Wolf-Hagen Schunck  Kidney International  Volume 67, Issue 1, Pages 248-258 (January 2005) DOI: 10.1111/j.1523-1755.2005.00075.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Tail-cuff blood pressure measurements were obtained at weeks 5, 6 and 7. (A)Treatments were begun at week 4. At week 5, the L-N(6)-(1-iminoethyl) lysine (L-NIL) and the L-NIL + eicosapentanoic acid (EPA)–treated groups had lower blood pressures. At week 7, blood pressure measurements of all groups were similar. (B) Cardiac hypertrophy was partially decreased by EPA alone and EPA in combination with L-NIL. (C) Albuminuria was markedly reduced by the EPA treatment without or with L-NIL, but slightly increased with L-NIL treatment alone. Kidney International 2005 67, 248-258DOI: (10.1111/j.1523-1755.2005.00075.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Glomerular inducible nitric oxide synthase (iNOS) staining in vehicle-treated double transgenic rat (dTGR), L-N(6)-(1-iminoethyl) lysine (L-NIL)-treated dTGR, eicosapentanoic acid (EPA)-treated dTGR, EPA + L-NIL–treated dTGR, and Srague-Dawley (SD) rats. L-NIL, L-NIL + EPA, and EPA alone all reduced iNOS staining. Kidney International 2005 67, 248-258DOI: (10.1111/j.1523-1755.2005.00075.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Renal interstitial fibrosis is shown as fibronectin staining in vehicle-treated double transgenic rat (dTGR), L-N(6)-(1-iminoethyl) lysine (L-NIL)–treated dTGR, eicosapentanoic acid (EPA)-treated dTGR, EPA + L-NIL–treated dTGR, and Srague-Dawley (SD) rats. Kidney International 2005 67, 248-258DOI: (10.1111/j.1523-1755.2005.00075.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Reactive oxygen species generation of glomeruli is shown as ethidium staining in vehicle-treated double transgenic rat (dTGR), L-N(6)-(l-iminoethyl) lysine (L-NIL)–treated dTGR, eicosapentanoic acid (EPA)-treated dTGR, EPA + L-NIL–treated dTGR, and Sprague-Dawley (SD) rats. Kidney International 2005 67, 248-258DOI: (10.1111/j.1523-1755.2005.00075.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Activating protein-1 (AP-1) and nuclear factor-kappaB (NF-κB) DNA binding activity in nuclear renal extracts by electrophoretic mobility shift assay (EMSA). (A) AP-1 activation was significantly reduced by the eicosapentanoic acid (EPA) treatments. (B) NF-κB activation was partially inhibited by EPA treatment. (C) EPA suppresses monocyte/macrophage (ED-1) infiltration in the kidney. Vehicle-treated and L-N(6)-(1-iminoethyl) lysine (L-NIL)–treated double transgenic rat (dTGR) kidneys showed increased infiltration of ED-1+ cells. Kidney International 2005 67, 248-258DOI: (10.1111/j.1523-1755.2005.00075.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 6 Representative high-pressure liquid chromatography (HPLC) chromatograms show the metabolite pattern produced during conversion of arachidonic acid (AA) and eicosapentanoic acid (EPA) by renal microsomes isolated from Sprague-Dawley (SD) control rats. (A) AA was converted to 19-/20-HETE and to a series of epoxyeicosatrienoic acids (EETs) and corresponding diols [dihydroxyeicosatrienoic acids (DHETs)]. EPA was hydroxylated to 19-/20-OH EPA and epoxidized predominantly to 17,18-EETeTr. AA and EPA hydroxylase (B and D) and AA and EPA epoxygenase (C and E) activities in renal microsomes were strongly reduced in double transgenic rat (dTGR) compared to Sprague-Dawley rats and were not influenced by the treatments. Western blotting for the cytochrome P450 enyzme (CYP4A) (F) revealed a significant increase in protein levels in the EPA treatment group compared to vehicle-treated dTGR. Microsomal CYP2C11 (G) was only increased by L-N(6)-(1-iminoethyl) lysine (L-NIL) alone compared to vehicle-treated dTGR but neither in the the EPA nor EPA + L-NIL–treated groups. Kidney International 2005 67, 248-258DOI: (10.1111/j.1523-1755.2005.00075.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 6 Representative high-pressure liquid chromatography (HPLC) chromatograms show the metabolite pattern produced during conversion of arachidonic acid (AA) and eicosapentanoic acid (EPA) by renal microsomes isolated from Sprague-Dawley (SD) control rats. (A) AA was converted to 19-/20-HETE and to a series of epoxyeicosatrienoic acids (EETs) and corresponding diols [dihydroxyeicosatrienoic acids (DHETs)]. EPA was hydroxylated to 19-/20-OH EPA and epoxidized predominantly to 17,18-EETeTr. AA and EPA hydroxylase (B and D) and AA and EPA epoxygenase (C and E) activities in renal microsomes were strongly reduced in double transgenic rat (dTGR) compared to Sprague-Dawley rats and were not influenced by the treatments. Western blotting for the cytochrome P450 enyzme (CYP4A) (F) revealed a significant increase in protein levels in the EPA treatment group compared to vehicle-treated dTGR. Microsomal CYP2C11 (G) was only increased by L-N(6)-(1-iminoethyl) lysine (L-NIL) alone compared to vehicle-treated dTGR but neither in the the EPA nor EPA + L-NIL–treated groups. Kidney International 2005 67, 248-258DOI: (10.1111/j.1523-1755.2005.00075.x) Copyright © 2005 International Society of Nephrology Terms and Conditions